AnaptysBio plunges as Eli Lilly drops arthritis drug from pipeline
Eli Lilly (NYSE:LLY) disclosed with its Q3 2024 financials on Wednesday that peresolimab, which was undergoing trials for ...
Nasdaq23 天
AnaptysBio price target lowered to $36 from $66 at JPMorgan
The firm says sentiment on AnaptysBio shares is “clearly negative” post the ANB032 failure and discontinuation in atopic dermatitis and Lilly’s peresolimab discontinuation. Street ...